NASDAQ$JAGX
Jaguar Health Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Jaguar Health's Mytesi net sales and gross sales increased in 2020 compared to 2019.
Jaguar Health, Inc. reported its financial results for the year ended December 31, 2020, with Mytesi net sales reaching approximately $9.3 million and gross sales at approximately $20.4 million, marking increases of 64% and 148%, respectively, compared to the previous year. The company's net loss for the year was $33.8 million, a decrease from the $38.5 million loss in 2019.
- Mytesi net sales increased by 64% year-over-year, reaching approximately $9.3 million.
- Mytesi gross sales increased by 148% year-over-year, reaching approximately $20.4 million.
- The company's net loss decreased by 12% year-over-year, from $38.5 million to $33.8 million.
- Operating expenses increased by 4% year-over-year, primarily due to inducement expense related to the Series B Convertible Preferred Stock and Series 3 Warrants.
Headline financials
Revenue & EPS history
Jaguar Health · Revenue · Quarterly
$2.58M
Revenue by segment
Jaguar Health · $20.3M total across 2 segments · Q1 2026
- Human Health$19.9M—98.3%
- Animal Health$345K—1.7%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2020
-6.2%
Avg return
Earnings day
-10.0%
Avg return
5 days after
-12.3%
Avg return
30 days after
24%
11 / 45 earnings
Positive
+23.1%
Q3 2023
Best reaction
-36.4%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.4% | -9.6% | — | |
| Q1 2026 | -5.0% | -13.6% | -37.9% | |
| Q3 2025 | +2.9% | -32.0% | -33.1% | |
| Q2 2025 | -17.9% | -25.9% | -24.3% | |
| Q1 2025 | +4.8% | -22.5% | -36.5% | |
| Q4 2024 | +8.8% | -12.6% | +144.8% | |
| Q3 2024 | -4.6% | -10.2% | -11.1% | |
| Q2 2024 | -10.8% | +5.8% | -7.5% | |
| Q1 2024 | -12.2% | -10.7% | -78.7% | |
| Q4 2023 | -17.8% | -6.7% | +150.0% | |
| Q3 2023 | +23.1% | +31.3% | -46.1% | |
| Q2 2023 | -10.8% | -12.6% | -44.9% | |
| Q1 2023 | -31.7% | -32.2% | -28.6% | |
| Q4 2022 | -31.0% | -44.4% | -51.3% | |
| Q3 2022 | -6.7% | -13.3% | -25.3% | |
| Q2 2022 | -8.8% | -8.6% | -32.6% | |
| Q1 2022 | -7.1% | -1.4% | -15.5% | |
| Q4 2021 | -7.4% | +12.8% | +42.5% | |
| Q3 2021 | -16.7% | -20.7% | -35.1% | |
| Q2 2021 | -12.8% | -15.0% | -34.8% | |
| Q1 2021 | -2.4% | +4.7% | +37.8% | |
| Q4 2020 | +13.8% | +14.4% | -13.2% | |
| Q3 2020 | -5.9% | +2.0% | +108.4% | |
| Q2 2020 | -21.3% | -15.3% | -36.5% | |
| Q1 2020 | -1.4% | -0.4% | -1.4% | |
| Q4 2019 | -5.9% | -6.5% | +2.0% | |
| Q3 2019 | -36.4% | -37.9% | -45.0% | |
| Q2 2019 | -23.9% | -27.7% | -16.4% | |
| Q1 2019 | +0.6% | +4.1% | -60.4% | |
| Q4 2018 | -9.8% | -23.9% | -38.6% | |
| Q3 2018 | -4.3% | -8.5% | -33.2% | |
| Q2 2018 | -12.4% | -19.9% | -50.3% | |
| Q1 2018 | -4.4% | -5.7% | -26.6% | |
| Q4 2017 | +4.6% | -1.1% | -9.3% | |
| Q3 2017 | -2.4% | -5.0% | -32.2% | |
| Q2 2017 | -6.3% | -15.4% | -19.7% | |
| Q1 2017 | -1.2% | -0.4% | -16.4% | |
| Q4 2016 | -1.1% | +10.3% | +16.1% | |
| Q3 2016 | -1.9% | -18.8% | -15.8% | |
| Q2 2016 | +3.4% | -6.1% | -23.1% | |
| Q1 2016 | +0.6% | — | — | |
| Q4 2015 | +5.6% | — | — | |
| Q3 2015 | +8.0% | — | — | |
| Q2 2015 | -1.7% | — | — | |
| Q1 2015 | -7.4% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro